公开(公告)号：US11377442B2

公开(公告)日：2022-07-05

申请号：US16008526

申请日：2018-06-14

申请人： ZANDER THERAPEUTICS, INC.

发明人： Harry M. Lander ,  David R. Koos

IPC分类号： A61K31/381 ,  A61K31/4025 ,  A61K31/4436 ,  C07D409/14 ,  C07D409/04 ,  C07D333/48 ,  A61K35/17 ,  A61K31/366 ,  A61K31/4245 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00

摘要： The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.

公开(公告)号：US10472351B2

公开(公告)日：2019-11-12

申请号：US16008631

申请日：2018-06-14

申请人： Zander Therapeutics, Inc.

发明人： Harry M. Lander ,  David R. Koos

IPC分类号： C07D407/12 ,  C07D333/48 ,  C07D407/04 ,  C07D407/14

摘要： The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

公开(公告)号：US20180346455A1

公开(公告)日：2018-12-06

申请号：US16008631

申请日：2018-06-14

申请人： Zander Therapeutics, Inc.

发明人： Harry M. Lander ,  David R. Koos

IPC分类号： C07D407/12 ,  C07D407/14 ,  C07D333/48 ,  C07D407/04

CPC分类号： C07D407/12 ,  C07D333/48 ,  C07D407/04 ,  C07D407/14 ,  C07D409/14

摘要： The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

公开(公告)号：US20200071307A1

公开(公告)日：2020-03-05

申请号：US16681763

申请日：2019-11-12

申请人： ZANDER THERAPEUTICS, INC.

发明人： Harry M. Lander ,  David R. Koos

IPC分类号： C07D407/12 ,  C07D409/14 ,  C07D407/14 ,  C07D333/48 ,  C07D407/04

摘要： The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.

公开(公告)号：US20190054118A1

公开(公告)日：2019-02-21

申请号：US15820334

申请日：2017-11-21

申请人： Zander Therapeutics Inc.

发明人： Harry M. Lander ,  David R. Koos

IPC分类号： A61K35/17 ,  C07D413/14 ,  C07D417/04 ,  C07D311/14 ,  C07D213/75 ,  C07D409/12 ,  C07D215/46 ,  C07D281/12 ,  C07D495/04 ,  C07D471/04 ,  C07D487/04 ,  C07D239/91 ,  C07D295/16 ,  C07D261/18 ,  C07D413/12

摘要： The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.